Abstract:Objective:To explore the targeted regulation of the inflammatory pathway and its mechanism after AMPK phosphorylation induced by lipopolysaccharide (LPS) in mice and human monocytes induced by THP-1, so as to provide evidence for the clinical application of Mogrol (MO) in the clinical treatment of acute lung injury.Methods:Twenty-four clean C57BL/6 male mice aged 6-8 weeks were randomly (random number) divided into the control group, MO group, LPS group and LPS+ MO group with 6 mice in each group. Mice in the control group were intraperitoneally injected with normal saline (30 mL/kg), mice in the MO group were intraperitoneally injected with MO (30 mg/kg), mice in the lipopolysaccharide group were intraperitoneally injected with lipopolysaccharide (10 mg/kg), mice in the lipopolysaccharide + MO group were intraperitoneally injected with MO (30 mg/kg), and the other side was injected with lipopolysaccharide (10 mg/kg) 30 min later. After 12 h, the mice were sacrificed for sampling and pathology and molecular biological tests were carried out. Cell experiment: THP-1 cells in good condition were cultured in RPMI 1640 medium containing 10% fetal bovine serum for 24 h, and then induced to differentiate into macrophages with 100 ng/mL PMA. The control group, MO group, LPS group and LPS + MO group were established. After drug stimulation, the cell suspension of each group was collected, and the cells and culture medium supernatants were used for subsequent detectionResults:Compared with the control group, the injury degree of the lipopolysaccharide group was obvious, the alveolar cavity structure was destroyed, the inflammatory cell infiltration was increased, and the alveolar septum was obviously thickened in the tissue sections. After MO intervention, the injury degree of lung tissue injury was greatly improved, and MPO and the lung wet/dry weight ratio were also significantly decreased. The mRNA levels of the inflammatory cytokines IL-1β, IL-6 and TNF- α in lung tissues were also significantly decreased under MO intervention [(2.96±0.10) vs. (5.53±0.14), (8.62±0.17) vs. (12.31±0.09), (3.01±0.09) vs. (4.85±0.36)]. The expression levels of NLRP3, caspase-1 p20, GSDMD-N and ASC in the lung tissues of mice in the lipopolysaccharide group were significantly higher than those in the control group, while the phosphorylation level of AMPK in the lipopolysaccharide + MO group was increased, and the expression of scorched death-related proteins was effectively inhibited [(0.58±0.09) vs. (0.89±0.15), (0.19±0.08) vs. (0.93±0.16), (0.65±0.09) vs. (0.86±0.14), (0.30±0.12) vs. (0.47±0.10), all P<0.05]. At the same time, the secretion of the inflammatory factors IL-1β and IL-18, the main markers of scorch death in the tissue measured by ELISA, could also be alleviated by MO. In the cell experiment, MO also promoted the phosphorylation of AMPK, inhibited the expression of proteins related to NLRP3 inflammatory bodies, and significantly improved cell viability. Conclusions:MO attenuates LPS-induced acute lung injury by inhibiting NLRP3-mediated cell pyrogenesis by promoting the phosphorylation of AMPK.

Inhibition of Myosin Light-Chain Kinase Enhances the Clearance of Lipopolysaccharide-Induced Lung Inflammation Possibly by Accelerating Neutrophil Apoptosis.

Inhibition of Non-Muscular Myosin Light Chain Kinase Accelerates the Clearance of Inflammatory Cells by Promoting the Lysosome-Mediated Cell Death

Time‑dependent changes in NLRP3 and Nrf2 levels in lipopolysaccharide‑induced acute lung injury

MLKL Protects Pulmonary Endothelial Cells in Acute Lung Injury

Correlation between protein C-1641A/-1654C haplotype and coagulation disorder in sepsis

Non-muscle Myosin Light Chain Kinase Isoform is a Viable Molecular Target in Acute Inflammatory Lung Injury.

Inhaled Neutrophil Elastase Inhibitor Alleviates Lipopolysaccharide Triggers Neutrophil Extracellular Trap-Mediated Acute Lung Injury via the MAPK/AKT/NLRP3 Pathway

The Role of P 38 MAPK Signaling Pathway in Macrophage Pyroptosis and Murine Acute Lung Injury

Regulation of the NLRP3 inflammasome and macrophage pyroptosis by the p38 MAPK signaling pathway in a mouse model of acute lung injury

MicroRNA-31-5p Exacerbates Lipopolysaccharide-Induced Acute Lung Injury Via Inactivating Cab39/AMPKα Pathway

Protectin D1 promotes resolution of inflammation in a murine model of lipopolysaccharide-induced acute lung injury via enhancing neutrophil apoptosis

MNK as a potential pharmacological target for suppressing LPS-induced acute lung injury in mice

MPLA inhibits release of cytotoxic mediators from human neutrophils while preserving efficient bacterial killing

Inhibition of GGPPS1 Attenuated LPS-induced Acute Lung Injury and Was Associated with NLRP3 Inflammasome Suppression.

LL-37 improves sepsis-induced acute lung injury by suppressing pyroptosis in alveolar epithelial cells

Inhibition of glycolysis alleviates lipopolysaccharide‐induced acute lung injury in a mouse model

Inhibition of PKR Ameliorates Lipopolysaccharide-Induced Acute Lung Injury by Suppressing NF-κB Pathway in Mice.

Inhibition of protein kinase C alpha attenuates lipopolysaccharide-triggered acute lung injury by alleviating the hyperinflammatory response and oxidative stress

Knockdown of phosphoinositide-dependent kinase 1 (PDK1) inhibits fibrosis and inflammation in lipopolysaccharide-induced acute lung injury rat model by attenuating NF-κB/p65 pathway activation

Inhibition of Neddylation Plays Protective Role in Lipopolysaccharide-Induced Kidney Damage Through CRL-mediated NF-κB Pathways.

FUNDC1 Regulates Autophagy by Inhibiting ROS-NLRP3 Signaling to Avoid Apoptosis in the Lung in a Lipopolysaccharide-Induced Mouse Model